As informed earlier regarding the health condition of MD, we would like to inform that the health update of MD appears to be progressively improving and it is in this regard that the Financial ....
Awaiting price reaction for this filing.
AJEL Limited informed BSE that its Board Meeting, originally scheduled for 30th May 2025 and then adjourned to 6th June 2025, has again been deferred. The meeting was meant to approve the Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March 2025. The delay is attributed to the health condition of the Managing Director, which the company says is 'progressively improving.' The company has committed to submitting the audited financial statements and the related audit report within one week, i.e., on or before 13th June 2025, and has apologized for the inconvenience to stakeholders. The communication is signed by Harshana Antharn, Wholetime Director.
This is a procedural/administrative filing with no financial numbers disclosed. Short-term investors may see mild negative sentiment due to the delay in announcing FY25 results, but the company has given a clear revised timeline of 13th June 2025. The note about the MD's health is a key governance-related disclosure worth monitoring.